Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

110.03 +1.36 (+1.25%)
Streaming Delayed Price Updated: 2:45 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,749,261
Open 110.78
Bid (Size) 110.03 (2)
Ask (Size) 110.06 (1)
Prev. Close 108.67
Today's Range 109.95 - 110.88
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 0.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities. 
Via Benzinga
Topics ETFs

Performance

YTD
+7.76%
+7.76%
1 Month
+0.28%
+0.28%
3 Month
-19.25%
-19.25%
6 Month
-18.87%
-18.87%
1 Year
+9.03%
+9.03%

More News

Read More
Technical Monday: Novo Nordisk, A Love Story
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Smart Money Is Betting Big In NVO Options
Via Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
Via Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Via Benzinga
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Via The Motley Fool
Vanity Trades Moving And The Weekly Moving Average Trigger
Via Talk Markets
Topics Stocks / Equities
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
Via Benzinga
Are Diet Drug Companies Over The Hump?
Via Talk Markets
Topics Stocks / Equities
Novo Nordisk Unusual Options Activity For November 19
Via Benzinga
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Via Investor's Business Daily
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
MDGL: A Promising Play In The Weight Loss Drug Space
Via Talk Markets
Topics Stocks / Equities
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Via Benzinga
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Via Benzinga
Is Novo Nordisk Stock a Buy Right Now?
Via The Motley Fool
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.